Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Completed · Phase 1/Phase 2

Conditions studied: Solid Tumor, Colorectal Cancer

In brief

The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).

Key facts

Study ID

NCT02953782

Run by

Gilead Sciences

People needed

78

Starts

2016-11-02

Expected to finish

2020-02-10

Last updated by the study team

2021-03-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCLA — Los Angeles, California, United States
• Stanford University — Palo Alto, California, United States
• Wayne State University — Detroit, Michigan, United States
• START Midwest — Grand Rapids, Michigan, United States
• UPENN — Philadelphia, Pennsylvania, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Md Anderson — Houston, Texas, United States
• START Center for Cancer Care — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.